Cynosure announced today the U.S. Food and Drug Administration (FDA) clearance of the Potenza radiofrequency (RF) microneedling device, the first and only FDA-cleared four-mode RF microneedling device. The Potenza device's four modes (monopolar or bipolar, delivered at either 1 MHz or 2 MHz frequency) offer customized microneedling treatments for patients and allow practitioners to deliver both shallow and deep treatments on a single system. The device is also equipped with Tiger Tip technology, a semi-insulated needle, which allows practitioners to expand the treatment zone and address more tissue per treatment. The device is also armed with a single-needle handpiece designed to target and improve blemishes. Potenza treatments use ultrafine needles and radiofrequency energy to penetrate the top layer of the skin and trigger the body's natural healing process to regenerate new collagen and elastin. "Our goal at Cynosure is to provide our customers with revolutionary technologies so they can consistently deliver outstanding results," says Todd Tillemans, CEO of Cynosure. "Potenza takes the microneedling category to a new level by offering unprecedented flexibility for doctors, which translates to personalized treatments and satisfied patients with exceptional outcomes."